Increased expression of HMGA1 correlates with tumour invasiveness and proliferation in human pituitary adenomas

Histopathology

Volumn 56, Issue 4, 2010, Pages 501-509

  Wang, Elaine Lu ^a   Qian, Zhi Rong ^a   Rahman, Md Mustafizur ^a   Yoshimoto, Katsuhiko ^a   Yamada, Shozo ^b   Kudo, Eiji ^a   Sano, Toshiaki ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TORANOMON HOSPITAL   (Japan)

Author keywords

HMGA1; Pituitary adenoma; Tumorigenesis

Indexed keywords

CORTICOTROPIN; FOLLITROPIN; HIGH MOBILITY GROUP A PROTEIN; HIGH MOBILITY GROUP A1 PROTEIN; LUTEINIZING HORMONE; PROLACTIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CANCER INVASION; CLINICAL FEATURE; HISTOPATHOLOGY; HUMAN; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOMA; ANIMALS; CASE-CONTROL STUDIES; CELL NUCLEUS; CELL PROLIFERATION; FEMALE; HMGA PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; PITUITARY NEOPLASMS; TUMOR BURDEN; UP-REGULATION;

MUS MUSCULUS;

EID: 77949614316     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03495.x     Document Type: Article

References (40)

1. Asa SL, Ezzat S. The pathogenesis of pituitary tumours. Nat. Rev. Cancer 2002 2 836 849.
2. Ezzat S, Asa SL. Mechanisms of disease: the pathogenesis of pituitary tumors. Nat. Clin. Pract. Endocrinol. Metab. 2006 2 220 230.
3. Reeves R, Nissen MS. The AT DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J. Biol. Chem. 1990 265 8573 8582.
4. Johnson KR, Lehn DA, Elton TS, Barr PJ, Reeves R. The chromosomal high mobility group protein HMG-I(Y): complete murine cDNA sequence, genomic structure, and tissue expression. J. Biol. Chem. 1988 18 18338 18342.
5. Saitoh Y, Laemmli UK. Metaphase chromosome structure: bands arise from a differential folding path of the highly AT-rich scaffold. Cell 1994 79 609 622.
6. Strick R, Laemmli UK. SARs are cis DNA elements of chromosome dynamics: synthesis of a SAR repressor protein. Cell 1995 83 1137 1148.
7. Du W, Thanos D, Maniatis T. Mechanisms of transcriptional synergism between distinct virus-inducible enhancer elements. Cell 1993 74 887 898.
8. Munshi N, Agalioti T, Lomvardas S, Merika M, Chen G, Thanos D. Coordination of transcriptional switch by HMGI(Y) acetylation. Science 2002 293 1133 1136.
9. Zhou X, Benson KF, Ashar HR, Chada K. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 1995 376 771 774.
10. Chiappetta G, Avantaggiato V, Visconti R et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 1996 13 2439 2446.
11. Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat. Rev. Cancer 2007 7 899 910.
12. Fedele M, Pentimalli F, Baldassarre G et al. Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 2005 24 3427 3435.
13. Hardy J. Transsphenoidal microsurgical treatment of pituitary tumours. In Linfoot J ed. Recent advances in the diagnosis and treatment of pituitary tumour. New York : Raven Press, 1979 375 888.
14. Qian ZR, Li CC, Yamasaki H et al. Role of E-cadherin, α-, β-, and γ -catenins, and p120 (cell adhesion molecules) in prolactinoma behavior. Mod. Pathol. 2002 15 1357 1365.
15. Sarhadi VK, Wikman H, Salmenkivi K et al. Increased expression of high mobility group A proteins in lung cancer. J. Pathol. 2006 209 206 212.
16. Nagpal S, Ghosn C, DiSepio D et al. Retinoid-dependent recruitment of a histone H1 displacement activity by retinoic acid receptor. J. Biol. Chem. 1999 274 22563 22568.
17. Giancotti V, Berlingieri MT, DiFiore PP, Fusco A, Vecchio G, Crane-Robinson C. Changes in nuclear proteins following transformation of rat thyroid epithelial cells by a murine sarcoma retrovirus. Cancer Res. 1985 45 6051 6057.
18. Giancotti V, Buratti E, Perissin L et al. Analysis of the HMGI nuclear proteins in mouse neoplastic cells induced by different procedures. Exp. Cell Res. 1989 184 538 545.
19. Chiappetta G, Bandiera A, Berlingieri MT et al. The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene 1995 10 1307 1314.
20. Fedele M, Battista S, Kenyon L et al. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 2002 21 3190 3198.
21. Qian ZR, Asa SL, Siomi H et al. Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Mod. Pathol. 2009 22 431 441.
22. Simpson DJ, McNicol AM, Murray DC et al. Molecular pathology shows p16 methylation in nonadenomatous pituitaries from patients with Cushing's disease. Clin. Cancer Res. 2004 10 1780 1788.
23. Simpson DJ, Hibberts NA, McNicol AM et al. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res. 2000 60 1211 1216.
24. Qian ZR, Sano T, Yoshimoto K et al. Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas. Lab. Invest. 2005 85 464 473.
25. Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987 330 566 568.
26. Qian ZR, Sano T, Asa SL et al. Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. J. Clin. Endocrinol. Metab. 2004 89 1904 1911.
27. Chang ZG, Yang LY, Wang W et al. Determination of high mobility group A1 (HMGA1) expression in hepatocellular carcinoma: a potential prognostic marker. Dig. Dis. Sci. 2005 50 1764 1770.
28. Abe N, Watanabe T, Izumisato Y et al. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms. J. Gastroenterol. 2003 38 1144 1149.
29. Balcerczak M, Pasz-Walczak G, Balcerczak E, Wojtylak M, Kordek R, Mirowski M. HMGI(Y) gene expression in colorectal cancer: comparison with some histological typing, grading, and clinical staging. Pathol. Res. Pract. 2003 199 641 646.
30. Liau SS, Jazag A, Whang EE. HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma. Cancer Res. 2006 66 11613 11622.
31. Turner HE, Nagy Z, Esiri MM, Harris AL, Wass JA. Role of matrix metalloproteinase 9 in pituitary tumor behavior. J. Clin. Endocrinol. Metab. 2000 85 2931 2935.
32. Hussaini IM, Trotter C, Zhao Y et al. Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. Am. J. Pathol. 2007 170 356 365.
33. Kim DH, Park YS, Park CJ et al. Expression of the HMGI(Y) gene in human colorectal cancer. Int. J. Cancer 1999 84 376 380.
34. Liau SS, Rocha F, Matros E, Redston M, Whang E. High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma. Cancer 2008 113 302 314.
35. Kolb S, Fritsch R, Saur D, Reichert M, Schmid RM, Schneider G. HMGA1 controls transcription of insulin receptor to regulate cyclin D1 translation in pancreatic cancer cells. Cancer Res. 2007 67 4679 4686.
36. Hibberts NA, Simpson DJ, Bicknell JE et al. Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin. Cancer Res. 1999 5 2133 2139.
37. Gazioglu NM, Erensoy N, Kadioglu P et al. Altered cyclin D1 genotype distribution in human sporadic pituitary adenomas. Med. Sci. Monit. 2007 13 457 463.
38. Trapasso F, Sarti M, Cesari R et al. Therapy of human pancreatic carcinoma based on suppression of HMGA1 protein synthesis in preclinical models. Cancer Gene Ther. 2004 11 633 641.
39. Scala S, Portella G, Fedele M, Chiappetta G, Fusco A. Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc. Natl Acad. Sci. USA 2000 97 4256 4261.
40. Chin MT, Pellacani A, Wang H et al. Enhancement of serum-response factor-dependent transcription and DNA binding by the architectural transcription factor HMG-I(Y). J. Biol. Chem. 1998 27 9755 9760.